Enterprise Value
77.42M
Cash
212.8M
Avg Qtr Burn
-27.77M
Short % of Float
22.96%
Insider Ownership
2.62%
Institutional Own.
99.09%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evorpacept (ALX148) + Herceptin® (trastuzumab)+Cyramza® (ramucirumab) and paclitaxel Details Cancer, Gastric cancer | Phase 2/3 Data readout | |
Evorpacept (ALX148) + Keytruda Details Cancer, Platinum-resistant ovarian cancer | Phase 2 Data readout | |
Evorpacept (ALX148) + Keytruda Details Head and neck cancer, Cancer | Phase 2 Data readout | |
Evorpacept (ALX148) combo w/ rituximab and lenalidomide Details Non-Hodgkin lymphoma, Cancer | Phase 1/2 Data readout | |
Evorpacept + enfortumab vedotin-ejfv/PADCEV® Details Cancer, Urothelial cancer | Phase 1 Data readout | |
Evorpacept (ALX148) + ENHERTU® Details Cancer, Breast cancer | Phase 1 Data readout | |
Evorpacept (ALX148) combo w/ azacitidine Details Myelodysplastic syndrome, Cancer | Failed Discontinued | |
Evorpacept (ALX148) + Venetoclax Details Cancer, Acute myeloid leukemia | Failed Discontinued | |
Evorpacept (ALX148) + Zanidatamab Details Breast cancer, Cancer | Failed Discontinued |